Akebia Therapeutics Files 8-K

Ticker: AKBA · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1517022

Akebia Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAkebia Therapeutics, Inc. (AKBA)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.00001
Sentimentneutral

Sentiment: neutral

Topics: filing, financials

Related Tickers: AKBA

TL;DR

AKBA filed an 8-K, mostly standard financial updates.

AI Summary

On January 13, 2025, Akebia Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Akebia Therapeutics is providing updated financial statements and disclosures to the SEC, which is standard practice for public companies.

Risk Assessment

Risk Level: low — The filing appears to be routine and does not disclose any immediate material adverse events or significant financial changes.

Key Players & Entities

  • Akebia Therapeutics, Inc. (company) — Registrant
  • 20250113 (date) — Filing Date
  • 245 First Street Cambridge, MA 02142 (address) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing for Akebia Therapeutics?

The filing is primarily for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

When was this 8-K report filed?

The report was filed on January 13, 2025.

What is Akebia Therapeutics' principal executive office address?

The address is 245 First Street, Cambridge, Massachusetts, 02142.

What is Akebia Therapeutics' IRS Employer Identification Number?

The IRS Employer Identification Number is 20-8756903.

What is the SIC code for Akebia Therapeutics?

The Standard Industrial Classification code is 2834, for Pharmaceutical Preparations.

Filing Stats: 817 words · 3 min read · ~3 pages · Grade level 10.3 · Accepted 2025-01-13 08:05:44

Key Financial Figures

  • $0.00001 — ich registered Common Stock, par value $0.00001 per share AKBA The Nasdaq Capital Marke

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. John P. Butler, President and Chief Executive Officer of Akebia Therapeutics, Inc. (the "Company"), plans to present the information in the presentation attached hereto as Exhibit 99.1 (the "Presentation") at the 43 rd Annual J.P. Morgan Healthcare Conference on January 16 th , 2025 at 7:30 a.m. PST. Spokespersons of the Company also plan to present the information in the Presentation at various meetings beginning on January 13, 2025, including investor and analyst meetings that coincide with the J.P. Morgan Healthcare Conference. A copy of the Presentation is attached as Exhibit 99.1 to this Current Report onForm8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Item 7.01 and Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing. By providing the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, the Company is not making an admission as to the materiality of any information herein. The information contained in this Current Report on Form 8-K is intended to be considered in the context of more complete information included in the Company's filings with the SEC and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press r

01. Other Events

Item 8.01. Other Events. The Company expects that its existing cash resources and cash from operations will be sufficient to fund its current operating plan, including the U.S. Vafseo launch and planned pipeline advancement, for at least two years. There can be no assurance that the current operating plan will be achieved in the time frame anticipated by the Company or that its cash resources will fund its operating plan for the period of time anticipated by the Company, or that additional funding will be available on terms acceptable to the Company, or at all.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Akebia Therapeutics, Inc. Presentation January 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AKEBIA THERAPEUTICS, INC. Date: January 13, 2025 By: /s/ John P. Butler Name: John P. Butler Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.